Valuation: MannKind Corporation

Market Cap 1.21B 1.08B 991M 905M 1.7B 114B 1.76B 11.95B 4.76B 60.64B 4.54B 4.44B 191B P/E 2026 *
-19.7x
P/E 2027 * 1,694x
Enterprise Value 1.21B 1.08B 991M 905M 1.7B 114B 1.76B 11.95B 4.76B 60.64B 4.54B 4.44B 191B EV / Sales 2026 *
2.74x
EV / Sales 2027 * 2.38x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+3.86%
1 week+10.86%
Current month+10.86%
1 month+4.58%
3 months-0.26%
6 months+8.99%
Current year-31.57%
1 week 3.46
Extreme 3.46
4.09
1 month 2.9
Extreme 2.895
4.09
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
25/9/26 Sell

Director

-39,051 0.0121%
10/9/26 Sell

Director

-33,558 0.0104%
7/8/26 Sell

Director

-39,051 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
+3.99%+10.86%-31.93%+5.43% 1.21B
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.34%+2.98%+24.79%+100.18% 57.62B
+2.44%+1.58%+28.79%+36.88% 43.65B
+5.86%+10.43%+23.05%+108.51% 44.03B
+9.01%+0.87%+214.40%+795.91% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.82%+2.76%+47.74%+132.96% 40.56B
Weighted average by Cap. +0.23%+2.45%+52.02%+138.93%

Financials

2026 *2027 *
Net sales 442M 396M 362M 331M 623M 41.54B 643M 4.37B 1.74B 22.16B 1.66B 1.62B 69.97B 507M 455M 416M 380M 715M 47.69B 738M 5.01B 2B 25.45B 1.9B 1.86B 80.33B
Net income -60.94M -54.66M -49.95M -45.6M -85.91M -5.73B -88.62M -602M -240M -3.06B -229M -224M -9.65B 1.18M 1.06M 966K 882K 1.66M 111M 1.71M 11.64M 4.64M 59.1M 4.42M 4.33M 187M
Net Debt - -
Projected Income Statement - Annual - MannKind Corporation
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
07/11/26 US$3.915 +4.12% 2,695,649
05/11/26 US$3.760 -4.33% 5,405,348
04/11/26 US$3.930 +5.36% 4,060,116
03/11/26 US$3.730 +2.19% 4,868,077
02/11/26 US$3.650 +4.29% 3,175,127
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MannKind Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.760USD
Average target price
8.083USD
Spread / Average Target
+114.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MannKind Corporation
  1. Stock Market
  2. Stocks
  3. MNKD Stock